Muscle proteolysis

Muscle proteolysis is the biological process of degrading skeletal muscle proteins, primarily mediated by the ubiquitin-proteasome system (UPS), the autophagy-lysosome pathway, and calpains (Sandri, 2013, Skeletal Muscle). In healthy individuals, this process is balanced by protein synthesis, but in pathological states like cancer cachexia, sarcopenia, and severe injury, accelerated proteolysis leads to significant muscle wasting (Fearon et al., 2012, Nature Reviews Clinical Oncology). The process is often driven by the upregulation of muscle-specific E3 ubiquitin ligases, such as MuRF1 (TRIM63) and MAFbx (FBXO32), which target myofibrillar proteins for degradation by the 26S proteasome (Bodine et al., 2001, Science). While "muscle proteolysis" is a critical therapeutic focus for preserving physical function and improving survival in chronic diseases, it represents a complex physiological pathway rather than a single druggable protein (Cohen et al., 2015, Nature Reviews Drug Discovery). Pharmacological interventions typically target specific components of this pathway, such as proteasome activity or upstream regulators like the myostatin/activin signaling axis, to mitigate muscle loss.

Other names

Muscle protein breakdownMyofibrillar proteolysisMuscle wastingSkeletal muscle proteolysis

Inhibition of the 26S proteasome, antagonism of the myostatin/activin signaling pathway, or modulation of E3 ubiquitin ligase activity to reduce protein degradation rates.